Concert Pharmaceuticals Inc (NASDAQ:CNCE) insider Value Fund L. P. Biotechnology sold 1,282,856 shares of the firm’s stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $26.65, for a total value of $34,188,112.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Concert Pharmaceuticals Inc (CNCE) opened at $25.60 on Friday. Concert Pharmaceuticals Inc has a one year low of $8.61 and a one year high of $30.71. The company has a market capitalization of $585.26, a P/E ratio of 6.88 and a beta of 1.67.

Hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in shares of Concert Pharmaceuticals in the third quarter valued at approximately $153,000. Alliancebernstein L.P. bought a new position in shares of Concert Pharmaceuticals in the second quarter valued at approximately $174,000. State of Wisconsin Investment Board bought a new position in shares of Concert Pharmaceuticals in the second quarter valued at approximately $181,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Concert Pharmaceuticals by 1.9% in the second quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock valued at $210,000 after purchasing an additional 287 shares in the last quarter. Finally, Airain ltd bought a new position in shares of Concert Pharmaceuticals in the second quarter valued at approximately $215,000. Institutional investors own 65.29% of the company’s stock.

A number of equities research analysts have commented on the company. Zacks Investment Research raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 15th. TheStreet raised Concert Pharmaceuticals from a “d” rating to a “c+” rating in a research note on Wednesday, November 29th. ValuEngine raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Mizuho assumed coverage on Concert Pharmaceuticals in a research note on Thursday, October 26th. They issued a “buy” rating and a $23.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of Concert Pharmaceuticals in a research note on Friday, October 20th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $24.83.

ILLEGAL ACTIVITY NOTICE: “Concert Pharmaceuticals Inc (CNCE) Insider Sells $34,188,112.40 in Stock” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/12/24/concert-pharmaceuticals-inc-cnce-insider-sells-34188112-40-in-stock.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.